

### PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg

Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_

Patient Preferred Location: \_\_\_\_\_

### <ICD 10 CODE REQUIRED> DIAGNOSIS & CLINICAL INFORMATION

**ICD 10 Code (PROVIDE COMPLETE CODE)**

M05. \_\_\_\_\_ Rheumatoid Arthritis, w/Rheumatoid Factor  
M06. \_\_\_\_\_ Rheumatoid Arthritis, w/o Rheumatoid Factor  
Other: \_\_\_\_\_

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.  
**LAB RESULTS:** Include Negative Hepatitis B within 3 years & Negative TB within 12 months.

### PRESCRIPTION\*

**Pre-Medications**

Acetaminophen: 650 mg PO  
Cetirizine: 10 mg PO  
Diphenhydramine: 25 mg PO  
Diphenhydramine: 25 mg IVP  
Famotidine: 20 mg PO  
Methylprednisolone: 125 mg SIVP  
Other: \_\_\_\_\_

**Lab Orders+**

Required: Negative TB, annually

**+ Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider**

**ORENCIA (abatacept)**

Infuse in 100 mL of 0.9% Sodium Chloride over at least 30 minues via pump with 0.2-micron filter

**Loading Dose**

**IV:** (wt < 60 kg): Infuse 500 mg (2 vials) at weeks 0, 2, 4  
**IV:** (wt 60 kg - 100 kg): Infuse 750 mg (3 vials) at weeks 0, 2, 4  
**IV:** (wt > 100 kg): Infuse 1000 mg (4 vials) at weeks 0, 2, 4

**Maintenance Dose (SELECT ONE)**

**IV:** (wt < 60 kg): Infuse 500 mg (2 vials) every 4 weeks for one year  
**IV:** (wt 60 kg - 100 kg): Infuse 750 mg (3 vials) every 4 weeks for one year  
**IV:** (wt > 100 kg): Infuse 1000 mg (4 vials) every 4 weeks for one year

Patient Weight: \_\_\_\_\_ lbs or \_\_\_\_\_ kg

**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

**Comments:**

\_\_\_\_\_  
\_\_\_\_\_

### PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_